A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)
Condition: Stage III Non-small-cell Lung Cancer Interventions: Drug: TQB2450; Drug: Anlotinib; Drug: TQB2450(blank); Drug: Anlotinib(blank) Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials